206 related articles for article (PubMed ID: 26077255)
1. Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.
de Lima LP; Seabra SH; Carneiro H; Barbosa HS
Antimicrob Agents Chemother; 2015 Sep; 59(9):5239-49. PubMed ID: 26077255
[TBL] [Abstract][Full Text] [Related]
2. Further evidence that naphthoquinone inhibits Toxoplasma gondii growth in vitro.
da Silva LL; Portes Jde A; de Araújo MH; Silva JL; Rennó MN; Netto CD; da Silva AJ; Costa PR; De Souza W; Seabra SH; DaMatta RA
Parasitol Int; 2015 Dec; 64(6):622-31. PubMed ID: 26335616
[TBL] [Abstract][Full Text] [Related]
3. Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.
Portes JA; De Souza W
Parasitol Res; 2019 Dec; 118(12):3479-3489. PubMed ID: 31728720
[TBL] [Abstract][Full Text] [Related]
4. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.
Portes JA; Souza TG; dos Santos TA; da Silva LL; Ribeiro TP; Pereira MD; Horn A; Fernandes C; DaMatta RA; de Souza W; Seabra SH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7374-86. PubMed ID: 26392498
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
7. New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Ferreira RA; de Oliveira AB; Gualberto SA; Miguel Del Corral JM; Fujiwara RT; Gazzinelli Guimarães PH; de Almeida Vitor RW
Exp Parasitol; 2012 Dec; 132(4):450-7. PubMed ID: 23000485
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous cystogenesis in vitro of a Brazilian strain of Toxoplasma gondii.
Paredes-Santos TC; Martins-Duarte ES; Vitor RW; de Souza W; Attias M; Vommaro RC
Parasitol Int; 2013 Apr; 62(2):181-8. PubMed ID: 23269201
[TBL] [Abstract][Full Text] [Related]
9. A new type of pterocarpanquinone that affects Toxoplasma gondii tachyzoites in vitro.
Portes Jde A; Netto CD; da Silva AJ; Costa PR; DaMatta RA; dos Santos TA; De Souza W; Seabra SH
Vet Parasitol; 2012 May; 186(3-4):261-9. PubMed ID: 22177332
[TBL] [Abstract][Full Text] [Related]
10. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Int J Exp Pathol; 1994 Apr; 75(2):111-6. PubMed ID: 8199003
[TBL] [Abstract][Full Text] [Related]
11. Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
Araujo FG; Khan AA; Remington JS
Antimicrob Agents Chemother; 1996 Jun; 40(6):1335-7. PubMed ID: 8725996
[TBL] [Abstract][Full Text] [Related]
12. Primary culture of skeletal muscle cells as a model for studies of Toxoplasma gondii cystogenesis.
Guimarães EV; de Carvalho L; Barbosa HS
J Parasitol; 2008 Feb; 94(1):72-83. PubMed ID: 18372624
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
14. Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.
Murata Y; Sugi T; Weiss LM; Kato K
PLoS One; 2017; 12(6):e0178203. PubMed ID: 28609444
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and ultrastructural assessment of atovaquone-proguanil hydrochloride combination in chronic murine toxoplasmosis.
Elmehankar MS; Elhenawy AA; Aboukamar WA; Elzoheiry MA; Nabih N
Ultrastruct Pathol; 2021 Nov; 45(6):376-383. PubMed ID: 34595988
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
17. [New pathogens and mode of action of azithromycin: Toxoplasma gondii].
Derouin F
Pathol Biol (Paris); 1995 Jun; 43(6):561-4. PubMed ID: 8539083
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of vertical transmission of Toxoplasma gondii in Calomys callosus model after reinfection with heterologous and virulent strain.
Franco PS; Silva DA; Costa IN; Gomes AO; Silva AL; Pena JD; Mineo JR; Ferro EA
Placenta; 2011 Feb; 32(2):116-20. PubMed ID: 21146211
[TBL] [Abstract][Full Text] [Related]
20. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.
Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM
Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
